A nurse is assessing a client who has a new skin lesion that has a wavy border. The nurse should document the lesion using which of the following descriptions?

Choice A reason:
Telling a client that they will be at an increased risk of breast cancer due to fibrocystic breast changes would be incorrect. Fibrocystic breast changes are not directly linked to an increased risk of breast cancer. While the presence of complex fibrocystic changes may slightly elevate the risk, fibrocystic breasts themselves are a common and benign condition.

Choice B reason:
It is not accurate to say that the manifestations of fibrocystic breasts often get worse after menopause. In fact, fibrocystic changes are related to hormone levels, and most women experience relief from these symptoms after menopause when hormone levels decline.

Choice C reason:
Stating that menopause won't have any effect on the manifestations is also incorrect. Menopause typically leads to a decrease in hormone levels, which are associated with fibrocystic breast changes. Therefore, most women see an improvement in their symptoms after menopause.

Choice D reason:
The most appropriate response is that the manifestations usually go away after menopause. Fibrocystic breast changes are linked to hormonal fluctuations, and after menopause, when these fluctuations cease, the symptoms of fibrocystic breasts typically resolve.

Choice A reason:

Danazol is a synthetic steroid that is typically used to treat endometriosis and fibrocystic breast disease. It is not indicated for the treatment of benign prostatic hyperplasia (BPH) and could potentially worsen symptoms due to its androgenic effects.

Choice B reason:

Methyltestosterone is an anabolic steroid with androgenic properties, similar to the male hormone testosterone. It is used to treat men with testosterone deficiency. However, it is not used for BPH treatment and, like danazol, could exacerbate BPH symptoms due to its androgenic activity.

Choice C reason:

Finasteride is a 5-alpha reductase inhibitor that is commonly prescribed for the treatment of BPH. It works by inhibiting the conversion of testosterone to dihydrotestosterone (DHT), a hormone that contributes to prostate growth. By reducing DHT levels, finasteride can help shrink the prostate and alleviate urinary symptoms associated with BPH.

Choice D reason:

Fluoxymesterone is another anabolic steroid with testosterone-like effects. It is used to treat conditions associated with a deficiency or absence of endogenous testosterone. It is not suitable for BPH treatment and could potentially worsen the condition due to its androgenic properties.